1. Zhang H, Yang X, Zheng F et al. Treatment for non-type 1 retinopathy of prematurity by intravitreal injection of anti-vascular endothelial growth factor drugs. 2022 April 27, PREPRINT (Version 1) available at Research Square [https://doi.org/10.21203/rs.3.rs-1560023/v1]
2. Good WV; Early Treatment for Retinopathy of Prematurity Cooperative Group.Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial.Trans Am Ophthalmol Soc. 2004;102:233-48.doi: 10.1097/IAE.0000000000001118
3. Fierson WM; AMERICAN ACADEMY OF PEDIATRICS Section on Ophthalmology; AMERICAN ACADEMY OF OPHTHALMOLOGY;et al .Screening Examination of Premature Infants for Retinopathy of Prematurity.Pediatrics.2018;142:e20183061. doi: 10.1542/peds.2018-3061.
4. Gupta MP, Chan RVP, Anzures R, et al .Practice Patterns in Retinopathy of Prematurity Treatment for Disease Milder Than Recommended by Guidelines.Am J Ophthalmol.2016;163:1-10. doi: 10.1016/j.ajo.2015.12.005.
5. Darlow BA, Lui K, Kusuda S, et al .International variations and trends in the treatment for retinopathy of prematurity.Br J Ophthalmol.2017;101:1399-1404. doi: 10.1136/bjophthalmol-2016-310041.
6. Liu T, Tomlinson LA, Ying GS, et al .Treatment of non-type 1 retinopathy of prematurity in the Postnatal Growth and Retinopathy of Prematurity (G-ROP) study.J AAPOS.2019;23:332.e1-332.e6. doi: 10.1016/j.jaapos.2019.08.279.
7. Sekeroglu MA, Hekimoglu E, Sekeroglu HT, et al.Retinopathy of prematurity: a nationwide survey to evaluate current practices and preferences of ophthalmologists.Eur J Ophthalmol.2013;23:546-52. doi: 10.5301/ejo.5000272.
8. Huang Q, Zhang Q, Fei P, et al.Ranibizumab Injection as Primary Treatment in Patients with Retinopathy of Prematurity: Anatomic Outcomes and Influencing Factors.Ophthalmology.2017;124:1156-1164. doi: 10.1016/j.ophtha.2017.03.018
9. Marlow N, Stahl A, Lepore D, et al .2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial.Lancet Child Adolesc Health.2021;5:698-707. doi: 10.1016/S2352-4642(21)00195-4.
10. Sankar MJ, Sankar J, Chandra P.Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.Cochrane Database Syst Rev.2018;1:CD009734. doi: 10.1002/14651858.CD009734.pub3.
11. Chiang MF, Quinn GE, Fielder AR, et al.International Classification of Retinopathy of Prematurity, Third Edition.Ophthalmology.2021;128:e51-e68. doi: 10.1016/j.ophtha.2021.05.031.
12. Rajan RP, Kohli P, Babu N, et al .Treatment of retinopathy of prematurity (ROP) outside International Classification of ROP (ICROP) guidelines.Graefes Arch Clin Exp Ophthalmol.2020;258:1205-1210. doi: 10.1007/s00417-020-04706-8.
13. Cheng Y, Zhu X, Linghu D, et al.Comparison of the effectiveness of conbercept and ranibizumab treatment for retinopathy of prematurity.Acta Ophthalmol.2020;98:e1004-e1008. doi: 10.1111/aos.14460.
14. Sukgen EA, Koçluk Y.Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity.Graefes Arch Clin Exp Ophthalmol.2019;257:49-55. doi: 10.1007/s00417-018-4168-5.
15. Mintz-Hittner HA, Kennedy KA, Chuang AZ; BEAT-ROP Cooperative Group.Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.N Engl J Med.2011;364:603-15. doi: 10.1056/NEJMoa1007374.
16. Ying GS, Pan W, Quinn GE, et al.Intereye Agreement of Retinopathy of Prematurity from Image Evaluation in the Telemedicine Approaches to Evaluating of Acute-Phase ROP (e-ROP) Study.Ophthalmol Retina.2017;1:347-354. doi: 10.1016/j.oret.2016.12.005.
17. Koucheki R, Isaac M, N Tehrani N, et al.Natural history and outcomes of stage 3 retinopathy of prematurity persisting beyond 40 weeks of post-menstrual age: Dilemma for treatment and follow up.Clin Exp Ophthalmol.2020;48:956-963. doi: 10.1111/ceo.13827.
18. Linghu D, Cheng Y, Zhu X, Deng X, Yin H, Jiang Y, Zhao M, Li X, Liang J. Comparison of Intravitreal Anti-VEGF Agents With Laser Photocoagulation for Retinopathy of Prematurity of 1,627 Eyes in China. Front Med (Lausanne). 2022;9:911095. doi: 10.3389/fmed.2022.911095.
19. Tan QQ, Christiansen SP, Wang J. Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: A meta-analysis and systematic review. PLoS One. 2019;14(12):e0225643. doi: 10.1371/journal.pone.0225643.
20. Wu Z, Zhao J, Lam W, et al. Comparison of clinical outcomes of conbercept versus ranibizumab treatment for retinopathy of prematurity: a multicentral prospective randomised controlled trial. Br J Ophthalmol. 2022;106(7):975-979. doi: 10.1136/bjophthalmol-2020-318026.
21. Honda S, Hirabayashi H, Tsukahara Y, et al. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2008;246:1061-3. doi: 10.1007/s00417-008-0786-7.
22. Wood EH, Rao P, Moysidis SN, et al. Fellow Eye Anti-VEGF 'Crunch' Effect in Retinopathy of Prematurity. Ophthalmic Surg Lasers Imaging Retina. 2018;49:e102-e104. doi: 10.3928/23258160-20180907-16.
23. Micieli JA, Surkont M, Smith AF. A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity. Am J Ophthalmol. 2009;148(4):536-543.e2. doi: 10.1016/j.ajo.2009.05.031.
24. Drenser KA. Anti-angiogenic therapy in the management of retinopathy of prematurity. Dev Ophthalmol. 2009;44:89-97. doi: 10.1159/000223949.
25. Klaassen I, van Geest RJ, Kuiper EJ, van Noorden CJ, Schlingemann RO. The role of CTGF in diabetic retinopathy. Exp Eye Res. 2015;133:37-48. doi: 10.1016/j.exer.2014.10.016.
26. Hartnett ME. Vascular endothelial growth factor antagonist therapy for retinopathy of prematurity. Clin Perinatol. 2014;41(4):925-943. doi: 10.1016/j.clp.2014.08.011.
27. Wu WC, Shih CP, Lien R, et al. SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER BEVACIZUMAB OR RANIBIZUMAB TREATMENT FOR RETINOPATHY OF PREMATURITY. Retina. 2017;37(4):694-701. doi: 10.1097/IAE.0000000000001209.
28. Chen X, Zhou L, Zhang Q, et al. Serum Vascular Endothelial Growth Factor Levels before and after Intravitreous Ranibizumab Injection for Retinopathy of Prematurity. J Ophthalmol. 2019;2019:2985161. doi: 10.1155/2019/2985161.
29. Cheng Y, Sun S, Deng X, et al. Systemic conbercept pharmacokinetics and VEGF pharmacodynamics following intravitreal injections of conbercept in patients with retinopathy of prematurity. Br J Ophthalmol. 2021:bjophthalmol-2021-319131. doi: 10.1136/bjophthalmol-2021-319131
30. Huang CY, Lien R, Wang NK, et al. Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2018 ;256(3):479-487. doi: 10.1007/s00417-017-3878-4.
31. Fidler M, Fleck BW, Stahl A, et al; RAINBOW study group†. Ranibizumab Population Pharmacokinetics and Free VEGF Pharmacodynamics in Preterm Infants With Retinopathy of Prematurity in the RAINBOW Trial. Transl Vis Sci Technol. 2020;9(8):43. doi: 10.1167/tvst.9.8.43.